Jeff Yass’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-37,300
| Closed | -$124K | – | 11309 |
|
|
2019
Q4 | $124K | Buy |
37,300
+17,700
| +90% | +$56.3K | ﹤0.01% | 9044 |
|
|
2019
Q3 | $60K | Buy |
+19,600
| New | +$55.1K | ﹤0.01% | 9736 |
|
|
2019
Q2 | – | Sell |
-28,800
| Closed | -$108K | – | 11164 |
|
|
2019
Q1 | $108K | Sell |
28,800
-13,400
| -32% | -$50.2K | ﹤0.01% | 8215 |
|
|
2018
Q4 | $151K | Sell |
42,200
-3,400
| -7% | -$14.8K | ﹤0.01% | 7976 |
|
|
2018
Q3 | $261K | Buy |
45,600
+18,400
| +68% | +$105K | ﹤0.01% | 7748 |
|
|
2018
Q2 | $136K | Buy |
27,200
+1,100
| +4% | +$5.66K | ﹤0.01% | 8908 |
|
|
2018
Q1 | $134K | Buy |
26,100
+900
| +4% | +$5.42K | ﹤0.01% | 8585 |
|
|
2017
Q4 | $151K | Buy |
+25,200
| New | +$152K | ﹤0.01% | 8486 |
|
|
2017
Q3 | – | Sell |
-34,100
| Closed | -$158K | – | 10006 |
|
|
2017
Q2 | $158K | Buy |
34,100
+15,700
| +85% | +$70.1K | ﹤0.01% | 8464 |
|
|
2017
Q1 | $91K | Buy |
+18,400
| New | +$177K | ﹤0.01% | 8427 |
|
Jeff Yass's FOMX Position: Q1 2020 in Review
Jeff Yass sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 74,496 shares — an estimated $248K sold.
Jeff Yass first reported a position in FOMX in Q2 2016 and held it in 9 quarters. The position peaked at $559K in Q3 2019. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Jeff Yass reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Jeff Yass sold 74,496 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $248K.
- Jeff Yass first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2016 and held it in 9 quarters.
- Jeff Yass's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $559K in Q3 2019.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.